angle-double-leftangle-double-rightcancelchevron-downcirclecircle-oclose-xangle-double-rightFacebookglobegoogleplusleft-openlinkedinmailmenuminusplusplus-circleplus-circle-outlinepopuprefreshright-opensearchsearch-plussort-downthin-leftthin-righttimes-circletwitter

Learn More About Our Investigation of Combining Chemotherapy and Immuno-Oncology Agents

Learn more about this combination

Read More About the Investigation of the Inducible T-Cell Costimulator (ICOS) Pathway

Learn more about ICOS

Learn More About How CC-486, an Investigational DNA Methyltransferase Inhibitor, Is Proposed to Work

Learn more about CC-486 here

Explore the Proposed Mechanism of Action of Durvalumab, a PD-L1 Inhibitor Being Investigated in Hematologic Malignancies

Learn more about Durvalumab here

View the Enrolling QUAZAR MDS Trial, Evaluating CC-486 in Patients With Low-Risk MDS

Learn more about the QUAZAR trial

Discover Celgene’s Pipeline
Explore Our Molecules in Phase 3 of Development

Explore Celgene's Phase 3 Molecules

Please Keep Me Informed

Provide your email address to receive monthly updates on Celgene’s research, news, and developments.

You are now leaving www.RESEARCHONCOLOGY.com, a website provided by Celgene. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. Celgene does not endorse and/or influence the content found on websites not owned/operated by Celgene.